{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:08:16Z","timestamp":1789823296613,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjmed.2026.07.042","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:57:58Z","timestamp":1785884278000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists and breast cancer: emerging evidence from prevention to treatment"],"prefix":"10.1016","author":[{"given":"Erika Bushatsky Andrade","family":"de Alencar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Libonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Drumond","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Y.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-0904","authenticated-orcid":false,"given":"Daniele","family":"Assad-Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3578-029X","authenticated-orcid":false,"given":"Danielle","family":"Laperche-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2026.07.042_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104710","article-title":"Association between body mass index and risk of breast cancer according to breast cancer subtypes: a systematic review and meta-analysis","volume":"86","author":"Dauccia","year":"2026","journal-title":"Breast"},{"issue":"15","key":"10.1016\/j.amjmed.2026.07.042_bib0002","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.2026.1114","article-title":"Obesity and cancer: a translational science review","volume":"335","author":"Shen","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.042_bib0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","volume":"17","author":"Levy","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.amjmed.2026.07.042_bib0004","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/OP-26-00485","article-title":"GLP-1 agonists are associated with a significant reduction in breast cancer incidence in women","volume":"22","author":"McDonald","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.amjmed.2026.07.042_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide-1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0006","article-title":"GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: a real-world analysis","volume":"44","author":"Gotera","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0007","article-title":"GLP-1 therapy and hormone receptor-positive breast cancer risk and survival: a real-world analysis","volume":"44","author":"Shah","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0008","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2026.44.16_suppl.1070","article-title":"Real-world survival benefit of GLP-1 RAs concomitant with CDK4\/6 inhibitors and endocrine therapy in HR+\/HER2\u2212 metastatic breast cancer","volume":"44","author":"Palleschi","year":"2026","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.042_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.12133","article-title":"Survival and recurrence with GLP-1 receptor agonists in breast cancer","volume":"9","author":"Tatum","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0010","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1200\/JCO.2026.44.16_suppl.3143","article-title":"Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors","volume":"44","author":"Orland","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0011","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2026.44.16_suppl.1100","article-title":"Impact of GLP-1 receptor agonists in HR+ breast cancer patients receiving CDK4\/6 inhibitors","volume":"44","author":"Patino","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.amjmed.2026.07.042_bib0012","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.2025.43.16_suppl.1115","article-title":"Concurrent GLP1R-agonist use with chemoimmunotherapy for early-stage triple-negative breast cancer","volume":"43","author":"Santos","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:24:56Z","timestamp":1789820696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326005929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":12,"alternative-id":["S0002934326005929"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.07.042","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and breast cancer: emerging evidence from prevention to treatment","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}